je.st
news
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA (pembrolizumab) in Solid Tumors
2015-04-20 14:00:00| Merck.com - Product News
Dateline City: MALVERN, Pa. & KENILWORTH, N.J. MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orTetraLogic Investor Relations:Pete A. Meyers, 610-889-9900, x103pete.meyers@tlog.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
combination
solid
evaluation
Category:Biotechnology and Pharmaceuticals